About William Petros
Dr. William P. Petros is Professor of Pharmaceutical Sciences, the Gates Wigner Endowed Chair, and Dean of the WVU School of Pharmacy.
Gates Wigner Dean of the WVU School of Pharmacy
- West Virginia University School of Pharmacy
- Office of the Dean
- West Virginia University School of Pharmacy
- Pharmaceutical Sciences
- PharmD, Philadelphia College of Pharmacy & Science, 1987
- BS, West Virginia University School of Pharmacy, 1983
Ten Most Recent:
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs GR, Peer CJ, Petros WP.
Cancer Chemother Pharmacol. 2014;73(5):991-997.
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M, Gibson LF, Remick SC, Wen S, Petros WP, Tse WW, Brundage KM, Vos JA, Cumpston AD, Bunner P, Craig M.
J Clin Oncol. 2013;31(35):4416-4423.
Duration of cisplatin excretion in breast milk.
Hays KE, Ryu RJ, Swisher EM, Reed E, McManus T, Rybeck B, Petros WP, Hebert MF.
J Hum Lact. 2013;29(4):469-472.
Three-dimensional hierarchical plasmonic nano-architecture enhanced surface-enhanced Raman scattering immunosensor for cancer biomarker detection in blood plasma.
Li M, Cushing SK, Zhang J, Suri S, Evans R, Petros WP, Gibson LF, Ma D, Liu Y, Wu NQ.
ACS Nano. 2013;7(6):4967-4976.
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros WP, Mueller MD, Yu JJ.
Oncol Rep. 2012;27(1):286-292.
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT((R))/leucovorin.
Peer CJ, McManus TJ, Hurwitz HI, Petros WP.
J Chromatogr B Analyt Technol Biomed Life Sci. 2012;898:32-37.
Effects of tobacco smoking and nicotine on cancer treatment.
Petros WP, Younis IR, Ford JN, Weed SA.
Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblasts.
Rellick SL, Piktel D, Walton C, Hall B, Petros WP, Fortney JE, Gencheva M, Denvir J, Hobbs GR, Craig M, Gibson LF.
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC.
Cancer Chemother Pharmacol. 2011;67(2):465-474.
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI.
Cancer Chemother Pharmacol. 2011;67(2):455-463.
- St. Jude Children’s Research Hospital , Post-Doctoral Fellow in Pharmacometrics/Immunotherapy (1987-1990)
- Philadelphia College of Pharmacy & Science, Pharm.D. (1987) Tampa VA Medical Center , Hospital Pharmacy Residency (1983-1984)
- West Virginia University School of Pharmacy, B.S. Pharmacy (1983)
- Hematology & Oncology
- Clinical drug development in oncology
- Pharmacokinetics and pharmacodynamics of new anti-cancer agents
- Clinical pharmacology of hematopoietic growth factors
- American Association for Cancer Research
- American Society of Clinical Oncology
- West Virginia University Cancer Institute
- American College of Clinical Pharmacy
- Hematology/Oncology Pharmacy Association
About William P. Petros
Dr. William P. Petros is Professor of Pharmaceutical Sciences, the Gates Wigner Endowed Chair, and Dean of the WVU School of Pharmacy. He is also Associate Director of Anti-Cancer Development and Director of the Clinical Pharmacology and Biospecimen Processing Cores at the WVU Cancer Institute. He has published over 100 articles in the areas of pharmacokinetics, pharmacogenomics and early phase anti-cancer drug studies. He received a BS in Pharmacy (WVU), Pharm.D (Philadelphia College of Pharmacy & Sciences) and a research fellowship (St. Jude Children’s Research Hospital.) He was continually funded as a principal or co-investigator on NIH, private foundation and pharma cancer-related grants for over 20 years.
The general focus of my research has entailed investigations concerning the clinical pharmacology of both cytokines and anti-cancer drugs. Most of the work has involved evaluation of anti-cancer drug pharmacometrics and pharmacogenetics in humans. The techniques typically entail: chromatography (HPLC +/- MS), pharmacometric modeling, and RT-PCR. The types of studies I have participated in range from those which involve traditional cytotoxic drugs in the high-dose setting to phase I (first in human) investigations of molecularly targeted agents.
I am also involved in the design and conduct of early phase treatment-related and research-related clinical trials in patients with cancer. Recent areas of focus include: development and evaluation of a drug to prevent fluorpyrimidine-induced palmar-plantar erythrodysesthesia; evaluation of drug dosing in obese patients; and elucidation of genetic factors related to chemotherapy-associated cognitive dysfunction.
My long term research goals include developing clinically feasible approaches which improve the selection and dosing of anti-cancer drugs for individual patients.